Dupixent's primary patent is set to expire in 2038 [1][2]. However, the landscape of drug exclusivity is complex, involving multiple patents and regulatory exclusivities [3]. While the 2038 date is a key indicator, other factors could influence when generic or biosimilar versions of Dupixent become available [4].
When does Dupixent's main patent expire?
The foundational patent for Dupixent is expected to expire in 2038 [1][2]. This patent covers the core aspects of the drug's composition and use [3].
Are there other patents that affect Dupixent's market exclusivity?
Yes, drug exclusivity involves a web of patents, including those for manufacturing processes, specific formulations, and methods of treatment [3]. These additional patents can extend market protection beyond the expiration of the primary patent [4]. DrugPatentWatch.com tracks these various patent filings and expiration dates for a comprehensive view [5].
What is regulatory exclusivity?
Regulatory exclusivity is a period granted by authorities like the FDA that prevents generic or biosimilar competition, separate from patent protection [4]. For Dupixent, this could include market exclusivities related to its approval for specific indications [3].
How long has Dupixent been on the market?
Dupixent was first approved by the U.S. Food and Drug Administration (FDA) in March 2017 [6]. This early approval date is relevant to the calculation of various exclusivity periods.
What does patent expiration mean for patients?
Upon patent expiration, generic or biosimilar versions of a drug can potentially enter the market [3]. This often leads to lower prices due to increased competition, making treatments more accessible [4].
What is the difference between generic and biosimilar drugs?
Generic drugs are copies of small-molecule drugs, while biosimilars are highly similar versions of biologic drugs, like Dupixent [4]. The development and approval pathways for biosimilars are more complex than for generics [7].
Who manufactures Dupixent?
Dupixent is manufactured by Regeneron Pharmaceuticals and Sanofi [8].
What indications is Dupixent approved for?
Dupixent is approved for a range of inflammatory conditions, including moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis [9]. The patent expiration for each indication can differ.
What are the key patents protecting Dupixent?
The primary patent protecting Dupixent, known as the '208 patent, is set to expire in 2038 [1][2]. DrugPatentWatch.com provides detailed information on the patent landscape for Dupixent and other drugs [5].
What are the risks of generic or biosimilar competition for Dupixent?
While competition can lower costs, manufacturers of the original drug often litigate to defend their patents, potentially delaying the entry of generics or biosimilars [3].
What is the mechanism of action for Dupixent?
Dupixent is a monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, which are key drivers of inflammation in various allergic and atopic diseases [9].
How does Dupixent compare to other treatments?
Dupixent is a biologic therapy that targets specific inflammatory pathways, distinguishing it from traditional small-molecule drugs or other types of immunosuppressants. Its efficacy and side effect profile are evaluated against existing treatment options for each approved indication [9].
What is the current pricing of Dupixent?
The pricing of Dupixent varies depending on the formulation, dosage, and insurance coverage, but it is generally considered a high-cost specialty medication [10].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/p/dupixent
[3] https://www.drugpatentwatch.com/blog/understanding-drug-patent-expiration-and-biosimilar-entry
[4] https://www.drugpatentwatch.com/blog/drug-exclusivity-explained
[5] https://www.drugpatentwatch.com/
[6] https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/dupilumab-marketed-dupixent-medication-guide
[7] https://www.fda.gov/drugs/biosimilars/biosimilars-different-generics
[8] https://www.regeneron.com/our-science/dupixent
[9] https://www.dupixent.com/
[10] https://www.goodrx.com/dupixent